Epidemiology of pertussis and haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis- inactivated poliovirus-haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: Implications for disease prevention in the United States

Pediatric Infectious Disease Journal

Volumn 28, Issue 6, 2009, Pages 521-528

  Greenberg, David P ^a,b   Doemland, Martha ^a   Bettinger, Julie A ^c   Scheifele, David W ^c   Halperin, Scott A ^d   Waters, Valerie ^e   Kandola, Kami ^f  

^a SANOFI PASTEUR   (France)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f Stanton Territorial Health Authority   (Canada)

Author keywords

Diphtheria tetanus acellular pertussis vaccines; DTaP IPV Hib vaccine; Epidemiology; Haemophilus influenzae type b polysaccharide vaccine; Inactivated poliovirus vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; CANADA; CHILD; EXPERIENCE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INCIDENCE; MEDLINE; PERTUSSIS; PRIORITY JOURNAL; REVIEW; TREND STUDY; UNITED STATES;

EID: 67649643550     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318199d2fc     Document Type: Article

References (57)

1. National Advisory Committee on Immunization (NACI). Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b combination vaccines presently approved for use in Canada for children <7 years of age. Can Commun Dis Rep. 2005;31(ACS-1):1-10.
2. Bettinger JA, Halperin SA, De Serres G, et al. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J. 2007;26:31-35.
3. Public Health Agency of Canada. National Advisory Committee on Immunization. Canadian Immunization Guide. 7th ed. Ottawa, Ontario: Canadian Medical Association; 2006:93:172-178, 257-266.
4. National Advisory Committee on Immunization (NACI). Statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep. 2000;26(ACS-1):1-8.
5. National Advisory Committee on Immunization (NACI). Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29(ACS-5):1-9.
6. Public Health Agency of Canada. Pertussis in Newfoundland and Labrador: 1991-2004. Can Commun Dis Rep. 2005;31:235-237.
7. Kandola K, Lea A, White W, et al. A comparison of pertussis rates in the Northwest Territories: Pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol. 2005;16:271- 274.
8. Health Canada. Case definitions for diseases under national surveillance. Can Commun Dis Rep. 2000;26(S3):101, 109.
9. Galanis E, King AS, Varughese P, et al. Changing epidemiology and emerging risk groups for pertussis. Can Med Assoc J. 2006;174:451-452.
10. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185:1448 -1453.
11. McWha L, MacArthur A, Badiani T, et al. Measuring up: results from the national immunization coverage survey, 2002. Can Commun Dis Rep. 2004;30:37-50.
12. Scheifele DW, Jadavji TP, Law BJ, et al. Recent trends in pediatric Haemophilus influenzae type b infections in Canada. Can Med Assoc J. 1996;154:1041-1047.
13. Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine. 1997;15:301-306.
14. De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child care centers and schools. Pediatr Infect Dis J. 1996;15:519-524.
15. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med. 1996;334:349-355.
16. Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four, and six months of age. Vaccine. 1998;16:576-585.
17. Centers for Disease Control and Prevention. Outbreaks of respiratory illness mistakenly attributed to pertussis - New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR. 2007;56:837-842.
18. Lievano FA, Reynolds MA, Waring AL, et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol. 2002;40:2801-2805.
19. Sotir MJ, Cappozzo DL, Warshauer DM, et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis. 2007;44:1216-1219.
20. Sotir MJ, Cappozzo DL, Warshauer DM, et al. A countywide outbreak of pertussis: initial transmission in a high school weight room with subsequent substantial impact on adolescents and adults. Arch Pediatr Adolesc Med. 2008;162:79-85.
21. Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics. 1999;104:e42.
22. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182:174 -179.
23. Public Health Agency of Canada. Notifiable Diseases Reporting System. Available at: http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c-time-e.html. Accessed August 20, 2008.
24. Scheifele DW, Halperin SA; members of the CPS/Health Canada; Immunization Monitoring Program, Active (IMPACT). Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis. 2003;14:213-219.
25. Le Saux N, Barrowman NJ, Moore DL, et al. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics. 2003;112: e348-e353.
26. Halperin SA. The control of pertussis-2007 and beyond. New Engl J Med. 2007;356:110-113.
27. British Columbia Centre for Disease Control, Statistics and Reports, Annual Reports. Available at http://www.bccdc.org/content.php?item = 33#0. Accessed August 20, 2008.
28. Scheifele D, Halperin S, Law B, et al; Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active (IMPACT). Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. Can Med Assoc J. 2005;172:53-56.
29. IMPACT highlights. Invasive Haemophilus influenzae type b cases-2004. Paediatr Child Health. 2005;10:314.
30. Scheifele DW, Bettinger JA, Halperin SA, et al; members of the Canadian Immunization Monitoring Program, Active (IMPACT). Ongoing control of Haemophilus influenzae b infections in Canadian children: 2004-7. Can J Infect Dis Med Microbiol. 2008;19:129. Abstract P45.
31. Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics. 2006;118:e421-e429.
32. Degani N, Navarro C, Deeks SL, et al; Canadian International Circumpolar Surveillance Working Group. Invasive bacterial diseases in Northern Canada. Emerg Infect Dis. 2008;14:34-40.
33. Parkinson AJ, Bruce MG, Zulz T; International Circumpolar Surveillance Steering Committee. International Circumpolar Surveillance, an Arctic network for surveillance of infectious diseases. Emerg Infect Dis. 2008;14: 18 -24.
34. Deeks SL, Degani N, Cottle T, et al. Invasive bacterial disease in the Canadian North [abstract]. In: Canadian Public Health Association Conference; May 28-June 1, 2006; Vancouver, BC.
35. Mahendra AS, Wilson SD, Deeks SL, et al. Invasive bacterial disease in the Canadian North. In: 6th Canadian Immunization Conference; Dec 5-8, 2004; Montreal, Quebec. Abstract P16.
36. Tsang RS, Mubareka S, Sill ML, et al. Invasive Haemophilus influenzae in Manitoba, Canada, in the postvaccination era. J Clin Microbiol. 2006;44: 1530-1535.
37. Tsang RS, Sill ML, Skinner SJ, et al. Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000-2006: invasive disease due to non-type b strains. Clin Infect Dis. 2007;44:1611-1604.
38. McConnell A, Tan B, Scheifele D, et al. Invasive infections caused by Haemophilus influenzae serotypes in twelve Canadian IMPACT centers, 1996-2001. Pediatr Infect Dis J. 2007;26:1025-1031.
39. Bruce MG, Deeks SL, Zulz T, et al. Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005. Emerg Infect Dis. 2008;14:48-55.
40. Halperin SA. Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACEL. Expert Opin Biol Ther. 2006;6:807-821.
41. Kohberger R, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy after a house contact using an efficacy model [abstract]. In: 8th International Pertussis Symposium, Saga of the genus Bordetella, 1906-2006; November 7-10, 2006; Paris, France.
42. Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine. Expert Rev Vaccines. 2005;4:793-805.
43. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003-3011.
44. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long-term protection after infant vaccination. Pediatr Infect Dis J. 2005;24:S104-S108.
45. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2005. MMWR. 2007;54:81.
46. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006; 55(RR-3):1-43.
47. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR. 2006;55(RR-17):1-37.
48. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18:326-382.
49. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115:1422-1427.
50. Wenger JD, Ward JI. Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein W, eds. Vaccines. 4th ed. Philadelphia, PA: WB Saunders Co; 2004:229-268.
51. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001;20:S10 - S18.
52. Edwards KM, Decker MD. Combination vaccines. Infect Dis Clin North Am. 2001;15:209-230.
53. Lee CY, Thipphawong J, Huang LM, et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics. 1999;103:25-30.
54. Bettinger JA, Halperin SA, De Serres G, et al. Epidemiology of hospitalized pertussis after change from whole-cell to acellular pertussis vaccine. 6th Canadian Immunization Conference 2004. CCDR. 2005:31.
55. Grewal S, Scheifele D. Haemophilus influenzae type b disease at 11 pediatric centres, 1996-1997. Can Commun Dis Rep. 1998;24:105-108.
56. Scheifele D, Halperin S; IMPACT Project Group. Haemophilus influenzae type b disease control using Pentacel, Canada, 1998-1999. Can Commun Dis Rep. 2000;26:93-96.
57. Scheifele D, Halperin S, Vaudry W, et al. Historic low Haemophilus influenzae type b case tally-Canada 2000. Can Commun Dis Rep. 2001;27: 149-150.